Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Also it uses human thrombin which means it could cause rejection responses.
That wouldn't impact revenue just profit or loss.
Seems like everyone is avoiding talking about what went wrong in Q4. Q3 was blockbuster but to hit the projected 15 million for 2017 each successive quarter needs to continue improving. Q4 revenue actually dropped by 100k from Q3. They increased products and sales area from Q3 to Q4 and revenue still decreased. Q1 will have to almost double Q4 if they want to get on track to make 15 million this year. The sell off doesn't surprise me. The pressure
is really on for Q1 numbers. If they come in 3 million or above things should be full steam ahead. If it comes in 2.1 million or less share price will be in big trouble.
I listened to conference call and was very disappointed that He did not discuss why revenue dropped from Q3.
E. Certain Restrictions on Subsequent Sales
The SPA contains certain restrictions on our ability to conduct subsequent sales of our equity securities. In particular, subject to certain customary exemptions,
from February 20, 2017 until 90 days after the closing of the 2017 Financing, neither the Company nor is subsidiary shall issue, enter into any agreement to issue
or announce the issuance or proposed issuance of any shares of Common Stock or securities convertible, exercisable or exchangeable for Common Stock.
Similarly, until such time as the three lead investors collectively own less than 20% of the Warrants purchased by them pursuant to the SPA, the Company is
prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of Common Stock or securities
convertible, exercisable or exchangeable for Common Stock (or a combination of units thereof) involving a Variable Rate Transaction.
Makes me nervous considering how much the Chinese rip off our tech. I would rather seen the company be commercially viable before presenting over there.
I made the same mistake. Regis cleared it up last night. Sulat only purchased about 180k. Check his link to 8k.
Good post. Thanks for the clarification. I did see that they can increase the blocker provision up to 9.99% with 61 day written notice. This may mean they won't sell as many quickly. We shall see.
Again thanks for your excellent DD
Sulat's bought it all! Honestly this should be looked at like a form 4. This is excellent news.
Not to rain on the parade but remember they did the shelf offering so basically they can right checks at will. I suspect that is why they aren't concerned about financing.
My guess. Low end mid 1 dollar range end of year. High end in line with recent analyst projections 2.50 to 3.00
They just 8k'd the time line change for 510k. That should speak volumes for how significant it is!
I listened to webcast. The corporate update they just put out covers presentation well with actually a little more detail than he spoke verbally. Tried to discern anything subtle. He said IDE for Internal clinic trial in U.S. would be linked to PMA pathway so do not expect internal trial announcement until late in year. He mentioned a "kit' doctors will receive when using AC5. That makes me think they are making progress with the 3rd party vendors. He said they are currently doing preclinical trials in other areas of use and the company will be sharing that info this year. I see this as significant work that is being going on that most of us don't see. Now referring to self assembling " materials" instead of peptides. Subtle change reflecting their increasing pipeline. He was very excited about truncated time frame for 510k. Over all reaffirmed my confidence in the management team. One day I think this is going to explode...when probably unexpectedly JMO
Unfortunately we are also do for another s filing. The company is down to 3.8 million. My guess is another 5 to 10 million of new dilution. With the current share price that should fund their plans until into 2018. Dr. Norchi has been pretty consistent with raising money with about 6 months of lead time.
A statement released earlier today by Roth Capital about Arch Therapeutics Inc (NASDAQ:ARTH) bumps the target price to $3.00
By Al Wild
Updated: February 14, 2017
Arch Therapeutics Inc (NASDAQ:ARTH) had its target price raised to $3.00 by Roth Capital in a report released 2/14/2017. The new target price indicates a possible upside of 3.62% based on the company's last stock close price.
Previously on 2/13/2017, Rodman & Renshaw reported about Arch Therapeutics Inc (NASDAQ:ARTH) raised the target price from $0.00 to $2.50. At the time, this indicated a possible upside of 2.85%.
Yesterday Arch Therapeutics Inc (NASDAQ:ARTH) traded -1.89% lower at $0.65. The company’s 50-day moving average is $0.64 and its 200-day moving average is $0.62. The last stock close price is up 4.01% from the 200-day moving average, compared to the S&P 500 which has increased 0.06% over the same time. 446,245 shares of the stock were exchanged, up from an average trading volume of 366,513
Analyst Coverage
Firm Analyst
Roth Capital Partners Michael Higgins
Rodman & Renshaw (A unit of H.C. Wainwright & Co.) Raghuram Selvaraju, Ph.D.
IFS Securities David Bouchey, Ph.D.
Maxim Group LLC Jason McCarthy, Ph.D.
Outstanding shares increased to 140 million.Not a huge increase but might explain why there continues to be so many shares for sale in the 60's
I just noticed and find this part of statement intriguing.
FRAMINGHAM, MA -- (Marketwired) -- 02/08/17 -- Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices. Is this yet another previously unmentioned pipeline product?
Arch has presented at Rodman Renshaw events multiple times. This is the first time R and R has initiated coverage. That tells me there is a significant change.
Yes. That is how I interpreted it.
It would be nice if the company would do a conference call for investors with a Q and A.
Interesting they are making a point of annoucing a corporate update. Could this mean they plan on sharing something substantial? Lets hope.
End of march. They have 90 days to file 10k.
I found it interesting that Dr. Norchi stated in todays press release that CE submission would be as soon as possible. It is the same thing he said at the early jan presentation. Tuesdays presentation he only said CE submission would be this year. This seemed to cause considerable speculation and consternation with investors. Guessing todays statement was in response to clarify and alleviate that concern.
Looks like webcast won't be available until tomorrow. Needed a password to access it live. That's a change from previous ones.
Tuesday the 31st
The ask is looking pretty thin. Any serious volume and this should move up significantly.
Agreed the potential for this company is exponential but they still have to focus on near term opportunities for revenue generation to be able to get to their potential.
A lot planned for this year. Just waiting on the public announcements.
2017 Planned Milestones
Announce grant for self-assembling peptidomimetics patent
Ø Submit and receive 510(k) for US commercialization (FDA)
Ø File and Receive CE Mark for EU commercialization
Ø File IDE for internal surgical clinical trial
Ø File additional patent application(s)
Ø Establish commercialization strategy
Ø Provide preclinical data on pipeline programs
additionally, really looking forward to this info.
Thanks Coin. Will do some dd.
Looks like attendance at Source Capital conference is invitation only. Guess that rules out me attending. NYC is close enough I could have. Would love to get one on one talk with Dr. Norchi.
It appears they are doing the same presentation circuit as last year. Assuming that means last year it was productive from a fund raising perspective.
Not to be pessimistic but my guess is all we get is a morsel or two. Nothing earth shattering.
IR told me back in the fall, Novalere was the original applicant so all FDA correspondence is with them.
Agreed, FYI they presented at the same conference last year. The one thing I find puzzling is why they have not announced the new patent they were granted this fall. Earlier in the year they were announcing all their new patents.
The company must believe it is less than a year. They have stated multiple times that they plan to commercialize AC5 in the same year they file the application. (that is a paraphrase of course)
The resistance has been showing much stronger than the support the last month or so.
Another one approved.
December 29, 2016
Drug Name and
Application Number
Active Ingredient
Dosage Form/ Route
Submission
Company
Submission Classification
Submission Status
Albuterol Sulfate and Ipratropium Bromide
ANDA #076724 Albuterol Sulfate; Ipratropium Bromide Solution; Inhalation SUPPL-12 Teva Pharms MANUF (CMC) Approved
Bendamustine Hydrochloride
ANDA #205447 Bendamustine Hydrochloride Powder; Iv (Infusion) ORIG-1 Breckenridge Pharm Approved
Clomipramine Hydrochloride
ANDA #074947 Clomipramine Hydrochloride Capsule; Oral SUPPL-16 Mylan LABELING Approved
Cyproheptadine Hydrochloride
ANDA #207783 Cyproheptadine Hydrochloride Tablet; Oral ORIG-1 Apex Pharms Inc Approved
Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate and Amp Sulfate
ANDA #040456 Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablet; Oral SUPPL-7 Actavis Elizabeth LABELING Approved
Fingolimod
ANDA #208559 Fingolimod Capsule; Oral ORIG-1 Msn Labs Pvt Ltd Tentative Approval
Fluticasone Propionate
ANDA #207957 Fluticasone Propionate Spray, Metered; Nasal SUPPL-2 West-Ward Pharms Int MANUF (CMC) Approved
If you take out the press releases announcing presentations at investment conferences there has really been only 1 press release since August telling the public about company advances. It is little wonder that this doesn't have more public awareness. To me the dearth of PR's explains the lack of upward movement. The faithful listen to the conference presentations and have their resolve re-enforced. The unenlightened are probably not listening to the presentations. The company spent more time updating investors through PR's in the first half of last year. Let's hope they do the same this year.
Arch is presenting at the 9th Annual Biotech showcase on 1/10.
http://www.ebdgroup.com/bts/core/presenting-companies.php?_ga=1.8631030.257338324.1483620854